摘要
环磷酸鸟苷(cGMP)信号通路介导的一氧化氮平滑肌舒张效应是正常勃起功能的必要条件。这个信号通路的下调能引起勃起功能障碍(erectile dysfunction,ED)的许多病理生理状况,并导致一些慢性疾病的发生,比如高血压和2型糖尿病。因此,选择性抑制cGMP降解酶能够促进性刺激的勃起反应。最近,一种新型的5-磷酸二酯酶(PDE-5)抑制剂他达拉非问世,该药有很长的半衰期。本文对其治疗ED的安全性研究进行了综述。
The cyclic nucleotide （cGMP） signalling pathway mediates the smooth-muscle relaxing effects of nitric oxide necessary for normal erectile function. Down-regulation of this pathway is the pathophysiological pivot of many forms of erectile dysfunction （ED） and leads to the development of some chronic diseases, such as hypertension and type 2 diabetes mellitus. Therefore, selective inhibition of the enzyme that catalyses the degradation of cGMP promotes erectile responses to sexual stimulation. Recently, a new phosphodiesterase type 5 （PDE-5） inhibitor tadalafil has emerged, which has a prolonged half-life. Here is a review of recent studies on the safety of tadalafil in the treatment of ED.
出处
《中华男科学杂志》
CAS
CSCD
2007年第8期762-764,共3页
National Journal of Andrology
